Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis

Introduction: MET amplification is a potentially actionable resistance mechanism in ALK-rearranged (ALK+) lung cancer. Studies describing treatment outcomes of this molecular subgroup are lacking. Methods: We assembled a cohort of patients with ALK+ lung cancer and acquired MET amplification (identi...

Full description

Bibliographic Details
Main Authors: Ibiayi Dagogo-Jack, MD, Lesli A. Kiedrowski, MS, MPH, Rebecca S. Heist, MD, MPH, Jessica J. Lin, MD, Catherine B. Meador, MD, PhD, Elizabeth A. Krueger, NP, Andrew Do, BS, Jennifer Peterson, BS, Lecia V. Sequist, MD, MPH, Justin F. Gainor, MD, Jochen K. Lennerz, MD, PhD, Subba R. Digumarthy, MD
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:JTO Clinical and Research Reports
Subjects:
ALK
MET amplification
Capmatinib
Crizotinib
Alectinib
Lorlatinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323000735

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323000735

Similar Items